Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at StockNews.com

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by StockNews.com to a “sell” rating in a report released on Friday.

Several other research firms have also recently weighed in on INO. Royal Bank of Canada cut their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research report on Wednesday. HC Wainwright reaffirmed a “neutral” rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a research report on Wednesday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Inovio Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $12.20.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO traded down $0.02 during trading hours on Friday, hitting $1.92. The company’s stock had a trading volume of 2,019,265 shares, compared to its average volume of 551,698. The business has a 50-day simple moving average of $2.04 and a 200-day simple moving average of $3.71. The stock has a market cap of $50.11 million, a price-to-earnings ratio of -0.91 and a beta of 0.92. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.18. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.03 million. On average, equities research analysts forecast that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Alpine Global Management LLC purchased a new position in shares of Inovio Pharmaceuticals during the fourth quarter valued at approximately $31,000. Stonepine Capital Management LLC purchased a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $1,922,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $412,000. Graham Capital Management L.P. purchased a new position in Inovio Pharmaceuticals in the 4th quarter worth approximately $114,000. Finally, Deutsche Bank AG raised its holdings in Inovio Pharmaceuticals by 524.6% in the 4th quarter. Deutsche Bank AG now owns 89,864 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 75,477 shares during the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.